Factors affecting response of chemotherapy in women with ovarian cancer

被引：0
|
作者：
Lubin, J. [1 ]
Markowska, A. [2 ]
Knapp, P. [3 ]
机构：
[1] Clin Oncol Poznan, Dept Gynecol, Poznan, Poland
[2] Inst Gynecol & Obstet, Poznan, Poland
[3] Univ Hosp Bialystok, Dept Gynecol, Bialystok, Poland
来源：
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2012年 / 33卷 / 06期
关键词：
Ovarian cancer; Chemotherapy; Factors affecting chemotherapy; MULTIDRUG-RESISTANCE GENE; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; PRODUCT P-GLYCOPROTEIN; PACLITAXEL RESISTANCE; PROTEIN LRP; E-CADHERIN; EXPRESSION; CLUSTERIN; MDR1; CYCLOOXYGENASE-2;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chemotherapy plays an important role in the treatment of ovarian cancer. Patients' response to chemotherapy is determined by a variety of acknowledged factors, but one might expect that many of them are yet to be described. The aim of this paper was to present the most essential yet still to be generally assessed in clinical practice, factors, which include: E-cadhedrin, hypoxia inducible factor alpha, survivin, COX-2, clusterin, BRCA1 protein, TP53 protein, YY1 protein, multidrug resistance protein, and interleukin-8.
引用
收藏
页码：644 / 647
页数：4
相关论文
共 50 条
  • [31] Mechanistic Insights on Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
    Huffman, Olivia G.
    Chau, Danielle B.
    Dinicu, Andreea I.
    DeBernardo, Robert
    Reizes, Ofer
    CANCERS, 2023, 15 (05)
  • [32] Changes in Depression and Sleep Quality and Associated Factors in Women Receiving Chemotherapy for Ovarian Cancer An Observational Study
    Wu, Hui-Ju
    Chuang, Chi-Mu
    Chien, Ching-Hui
    Wang, Tsae-Jyy
    Liang, Shu-Yuan
    CANCER NURSING, 2022, 45 (04) : 271 - 279
  • [33] Factors Affecting Risk of Mortality in Women With Vaginal Cancer
    Shah, Chirag A.
    Goff, Barbara A.
    Lowe, Kimberly
    Peters, William A., III
    Li, Christopher I.
    OBSTETRICS AND GYNECOLOGY, 2009, 113 (05) : 1038 - 1045
  • [34] Toxicities, complications, and clinical encounters during intraperitoneal chemotherapy in 17 women with ovarian cancer
    Sun, Virginia
    Otis-Green, Shirley
    Morgan, Robert
    Wakabayashi, Mark
    Hakim, Amy
    Callado, Maria Elenita
    Yang, Eunice
    Ferrell, Betty
    Grant, Marcia
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2013, 17 (03) : 375 - 380
  • [35] For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon, Don S.
    Restivo, Antonella
    Lomme, Michelle
    Charbonneau, Nicole
    Brard, Laurent
    Hughes, Tasha
    Weitzen, Sherry
    Legare, Robert
    Granai, C. O.
    DiSilvestro, Paul
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (01): : 39 - 42
  • [36] Risk factors for venous thromboembolism in patients undergoing neoadjuvant chemotherapy as treatment for ovarian cancer
    Ward, Alistair
    Dampali, Roxani
    Wang, Wanxin
    Sclavi, Sofia Bertoni
    Khalil, Habib R.
    Touloumis, Anestis
    Devaja, Omer
    Papadopoulos, Andreas J.
    Montalto, Stephen Attard
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2025, 305 : 292 - 297
  • [37] Chemotherapy of ovarian cancer in elderly patients
    Troso-Sandoval, Tiffany A.
    Lichtman, Stuart M.
    CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 292 - 301
  • [38] Neoadjuvant chemotherapy in ovarian cancer revisited
    Mahner, S.
    Trillsch, F.
    Chi, D.
    Harter, P.
    Pfisterer, J.
    Hilpert, F.
    Burges, A.
    Weissenbacher, T.
    du Bois, A.
    ANNALS OF ONCOLOGY, 2016, 27 : 30 - 32
  • [39] Factors of the ovarian cancer resistance to combined chemotherapy with platinum preparations
    Blyumenberg, AG
    Gorbacheva, LB
    Gorbunova, VA
    Kozachenko, VP
    Lankin, VZ
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 1996, 122 (12) : 1213 - 1216
  • [40] Attitudes to chemotherapy in patients with ovarian cancer
    Penson, RT
    Dignan, F
    Seiden, MV
    Lee, H
    Gallagher, CJ
    GYNECOLOGIC ONCOLOGY, 2004, 94 (02) : 427 - 435
12345